Information détaillée
Avis
L'information est fournie dans la langue dans laquelle le ou la bénéficiaire l'a présentée.
- Titre du projet :
- Dominant genetics of cohesin pathway proteins to kill cancer
- Chercheur principal :
- Stirling, Peter C
- Co-chercheurs :
- S/O
- Directeur(s) de recherche :
- S/O
- Établisssement payé :
- University of British Columbia
- Établissement de recherche :
- BC Cancer, part of PHSA (Vancouver)
- Département :
- Terry Fox Laboratory
- Programme :
- Subvention Projet
- Concours (année/mois) :
- 202209
- CEP désigné :
- Biochimie et biologie moléculaire - B
- Institut principal :
- Génétique
- Thème principal :
- Recherche biomédicale
- Durée (année/mois) :
- 5 ans 0 mois
- Contribution des IRSC :
- Donateurs :
- Montant :
- 883 575$
- Équipement :
- 0$
- Contribution du partenaire externe :
- Nom du partenaire :
- S/O
- Montant :
- S/O
- Équipement :
- S/O
- Partenaire du candidat à l'externe :
- Nom du partenaire :
- S/O
- Montant :
- S/O
- Équipement :
- S/O
- Partenaire externe (en nature) :
- Nom du partenaire :
- S/O
- Montant :
- S/O
- Équipement :
- S/O
- Mots clés :
- Dominant Genetics; Genome Instability; Missense Mutations; Mutational Scanning; Protein Trapping; Smc Atpases; Synthetic Lethality
- Résumé :
- Cancer cells make a lot of mistakes as they divide and grow. This allows them to accumulate mutations in their DNA which can fuel cancer development. However, sloppy maintenance of their DNA also makes cancer cells vulnerable to therapies which attack this mechanism. Unfortunately only a handful of such therapies exist, making it difficult for clinicians to apply targeted or personalized approaches in this setting. We are studying a group of proteins involved in holding chromosomes together called cohesins that work to maintain a stable genome, and therefore could be good targets for cancer therapy. We will create models in the lab that can better represent what would happen if we had specific cohesin targeting drugs. Then we will use this knowledge to help identify which specific patients could benefit from such drugs. Our models can also tell us where and how new drugs might work to inhibit cohesin proteins, fueling future drug discovery efforts. Overall, this project will open up new prospects for cancer patients with an increased toolbox for therapeutic target identification and validation.
- Version :
- 20250311.1